Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
| Product: | Crystaderm |
| Active Ingredient: | Hydrogen peroxide 1%w/w |
| Dosage Form: | Topical cream |
| New Zealand Sponsor: | AFT Pharmaceuticals Limited |
| Manufacturers: | Mayne Pharma International Pty Limited, Adelaide, Australia Bioglan AB, Malmo, Sweden |
| Product: | Lynparza |
| Active Ingredient: | Olaparib 100mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | AstraZeneca Limited |
| Manufacturers: | AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany AbbVie Limited, Barceloneta, Puerto Rico |
| Product: | Lynparza |
| Active Ingredient: | Olaparib 150mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | AstraZeneca Limited |
| Manufacturers: | AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany AbbVie Limited, Barceloneta, Puerto Rico |
Dated this 13th day of March 2020.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).